While the FDA approves drugs for specific indications, off-label use is often supported by clinical studies, case reports, and professional guidelines. Oncologists rely on published literature and expert consensus to justify the off-label use of a drug. Institutional review boards and multidisciplinary tumor boards also play a role in evaluating the appropriateness of off-label treatments.
